Nuvectra — Investor Presentation (January 2018)
23 slides from Nuvectra's investor presentation, Jan 8, 2018
Slide 1: Investor Presentation: New Directions in Neurostimulation
NUVECTRA Investor Presentation New Directions in Neurostimulation pe January 2018
Slide 2: Legal Disclaimer
Legal Disclaimer Forward Looking Statements This presentation contains "forward-looking statements,” including statements we make regarding the outlook for Nuvectra as an independent publicly-traded company. Forward-looking statements are based only on our current beliefs, expectations and assumptio
Slide 3: Investment Highlights
Investment Highlights Significant revenue growth opportunity in large, established markets ~$40M+ Algovita™ annualized revenue run-rate() in Q4’17 Proven commercial success with over 1,000 US Algovita™ implants Neurostimulation platform technology and IP with broad range of applications Improving sa
Slide 4: Nuvectra Positioned for Success
Nuvectra Positioned for Success Large & Growing Platform Algovita™ SCS Target Markets Technology System ~$3.4B *Spinal Cord + Expansive +Powerful IPG Stimulation (SCS) IP portfolio i +: Four stim modes Sacral +Access to multiple Neuromodulation markets & +Stretchable leads (SNM) indications + Discre
Slide 5: Neurostimulation Targeted Market Opportunity
Neurostimulation Targeted Market Opportunity ~$3.4B Target Market) ~10% CAGR through 2020 SNM Market?) DBS Market®) “ 2B% Chronic Pain Bladder & Bowel Control Movement Disorders ~$2.0B ~$690M ~$650M ~11% CAGR ~8% CAGR ~9% CAGR $2,520 $2,710 $2,280 an $780 Hl il wl HT [ ill 2016 2017 2018 2019 2020 2
Slide 6: Revenue Growth Driven by Algovita Adoption
Revenue Growth Driven by Algovita™ Adoption (Unaudited) $11.5-12.0 ee mNeuroNexus m Services $10 mAlgovita Revenue ($M) a B $10.0-10.5 $4.2 $4 2.6 $2.1 : . i $0 90.6 Q116 §=Q2/16 §=Q3/16 Q4/16 Q1N17 Q27 Q3/17 Q4NTE $2.0 $1.2 Algovita™ QoQ sequential growth % 37% 105% 73% 68% 62% 15% 64% Total YoY gr
Slide 7: Platform Designed for Multiple Indications
Platform Designed for Multiple Indications ive Proprietary IP Por 192 Issued 142 ae Pending Physician & Patient Programmers Proprietary Processors NUVECTRA swe
Slide 8: SCS — Our First Opportunity
SCS — Our First Opportunity Chronic Pain\".2) + 1.5B WW suffer from chronic pain Chronic pain is a + 100M Americans suffer from severe and chronic pain significant medical, economic and social problem + $300B annual healthcare spend in the US + Chronic pain sufferers are also affected with depressio
Slide 9: Experienced Leadership Team
Experienced Leadership Team & Scott Drees | CEO & Director . + QIG Group, CEO & Founding Partner if + Founding Division President, Advanced Neuromodulation Systems Inc. (ANSI) + Prior experience: St. Jude Medical, Boston Scientific, Johnson & Johnson + 36 yrs. implantable medical devices experience;
Slide 10: Algovita SCS System
Algovita™ SCS System Designed to Improve Patient Outcomes NUVECTRA
Slide 11: Powerful IPG Therapy Delivery
Powerful IPG Therapy Delivery Four Stimulation Modes + High fidelity tonic + Burst programming Baas 5 ie ~ A + Ultra high pulse width Beer Wen CR + High frequency Algovita’ NUVECTRA Proprietary Stimulation & Power Processors = =A a ‘oot \ Si Configuration 3x8 2x12 2x8 # of Channels 24 16 # of Power
Slide 12: New Generation of Percutaneous Lead Design
New Generation of Percutaneous Lead Design Key Capabilities + Lead elongation (stretchability) + Kink-resistant + Reduce lead migration (13%) 4 + Reduce lead breakage (9%) + Increased spinal coverage STRANDED WIRE DUAL COIL DESIGN 8-Electrode Leads 8 & 12-Electrode Leads Competitors Algovita World’s
Slide 13: New Generation of Surgical/Paddle Leads
New Generation of Surgical/Paddle Leads + Reduced length and thickness + Stretchable lead body and single lead tail + Steerable stylet and posterior stabilizing ribs + Multi-midline electrode configuration S + Two placement options <— — Traditional placement — Direct visual placement (articulating h
Slide 14: Simplifying Programming Complexity
Simplifying Programming Complexity Patient Clinician + Wireless telemetry + Icon-based color touchscreens * Highly intuitive + Patient interactive programming + Smallest patient controller Competitive Devices") MDT Patient Controllers Patient IPG Rechargers NUVECTRA
Slide 15: U.S. Commercialization
U.S. Commercialization Hire Proven Selling Team Sales management, national account coverage, direct reps, sales agents, clinical specialists + U.S. Algovita™ sales team of ~70 employees + 45 active territories, as of December 31, 2017 2017 Quarterly Rep Productivity ~$220K Qi NUVECTRA Capture Market
Slide 16: Post-Market Clinical Data Strategy
Post-Market Clinical Data Strategy Four-arm post-market study + Designed to study real-world outcomes of the four stimulation modes offered by the Algovita™ SCS system — High fidelity tonic —- Burst programming — Ultra high pulse width — High frequency Initial study arm & timing * Compare outcomes o
Slide 17: Algovita MRI Conditional Regulatory Strategy: CE Mark
Algovita™ MRI Conditional Regulatory Strategy: CE Mark i Bostong Wt ‘ Medtronic Scientific CT) Abbott ave NUVECTRA Montage / Precision — = System Intellis Spectra Protégé MRI Senza Algovita Approval Full Body Full Body Head & Extremities Full Body Full Body Strength 1.57 1.57 1.57 1.57 &3T 1.57 Full
Slide 18: Algovita MRI Conditional Regulatory Strategy: FDA
Algovita™ MRI Conditional Regulatory Strategy: FDA i Boston, wth ‘ Medtronic Scientific (= amaaed nevro NUVECTRA Montage / Precision ae = System Intellis peels Protégé MRI Senza Algovita Approval Full Body Full Body Head & Extremities Head & Extremities Full Body! Strength 1.5T 1.57 &3T ad Only Head
Slide 19: Virtis Sacral Neuromodulation System
Virtis™ Sacral Neuromodulation System) Market Opportunity + ~400M incontinence patients worldwide) + ~$690 million market) * 20+ yrs. proven efficacy * 225,000+ WW implants) + Established reimbursement Commercial Strategy + Regulatory submissions filed with FDA and CE Mark authorities Virtis™ is ind
Slide 20: SNM System Comparison
SNM System Comparison) =) InterStim InterStim II | Virtis™() Head (Heat 1 1or2 Lead Fixation Tines | Fins | Reinforced Lead Body No Yes, Braid Lead Lengths 28,33,41 em | 30,40 em | Battery / Primary Cell Primary Cell Rechargeable Battery Life 7 years 4.4 years 10 years Voltage ll Current | Inductive
Slide 21: Strategic Development Agreement
Strategic Development Agreement + Development agreement through 2018!) + Nuvectra to license platform of IPG and programmers to Aleva for royalties + Aleva provides MEMS technology with directSTIM directional DBS lead + Field of use: DBS for Parkinson's Disease (PD) and Essential Tremor (ET) NUVECTR
Slide 22: Investment Highlights
Investment Highlights Significant revenue growth opportunity in large, established markets ~$40M+ Algovita™ annualized revenue run-rate() in Q4’17 Proven commercial success with over 1,000 US Algovita™ implants Neurostimulation platform technology and IP with broad range of applications Improving sa
Slide 23: Frost & Sullivan 2017 New Product Innovation Award
F RUQgSatee? SU Lali iVAGN Nuvectra’s Spinal Cord Stimulator : ae ene Receives Frost & Sullivan's AWARD 2017 New Product Innovation Award NUVECTRA